90,000 sq. ft. Expansion of Grand River Aseptic Manufacturing’s Finishing and Warehouse Center is Complete

February 27, 2024

GRAM Expands to Meet Growing Pharma Manufacturing Demands

 Grand River Aseptic Manufacturing (“GRAM”), a leading sterile injectable contract manufacturer of biologics, small molecules, and vaccines, announces the completion of its finishing and warehouse center expansion. The expansion added 90,000 sq. ft. to the existing 110,000 sq. ft., totaling 200,000 sq. ft. of sophisticated inspection, packaging, testing, and warehouse capabilities.


Grand River Aseptic Manufacturing is known for its state-of-the-art technology, world-class facilities, customer-centric team, and Annex 1 compliance. GRAM’s expansion of additional capabilities and systems supports an industry-wide need for syringe, cartridge, and vial filling and finishing, as well as the growth in advanced drug delivery systems.


“The increase in capabilities, capacity, and redundancy from this expansion sustains GRAM’s commitment to delivering quality products and supporting our partners with contract manufacturing that aligns with their needs,” said Tom Ross, President and CEO of Grand River Aseptic Manufacturing. “GRAM’s authenticity and transparency with our partners and component manufacturers allow us to serve with intention and continue our growth. I look forward to welcoming new and current customers to see all we offer.”


The 200,000 sq. ft. finishing and warehouse center will incorporate:

  • Four fully automated inspection systems (Korber and Optrel), eight semi-automated (Dabrico), and twelve manual inspection booths.
  • Four labeling and packing lines (Dividella, Uhlmann, Bausch + Ströbel, Marchesini) with future label and pack space.
  • Two autoclaves for product terminal sterilization.
  • QC analytical and sterility lab with sterility isolators (SKAN) to support lyophilized, biologics, and small molecule product testing.
  • Three -50°C walk-in freezers and three walk-in finished product (2-8°C and -20°C) refrigerated frozen units.
  • 30,000 sq. ft. reserved for additional syringe/cartridge filling lines.
  • Over 50,000 sq. ft. of material and finished product storage.


Grand River Aseptic Manufacturing’s finishing and warehouse center compliments its recently expanded cutting-edge filling facility, which includes four Bausch + Ströbel filling lines with SKAN isolator technology to manufacture clinical and commercial scale liquid vials, lyophilized vials, syringes, and cartridges. With over 100 million units of capacity, GRAM is ready to support pharma and biotech customers further


About Grand River Aseptic Manufacturing, Inc.
Grand River Aseptic Manufacturing, Inc., a prominent aseptic fill-finish contract development and manufacturing organization, delivers biologics, small molecules, and vaccine capabilities for liquid and lyophilized vials, syringes, and cartridges. Grand River Aseptic Manufacturing’s 300,000 sq. ft. of sophisticated GMP space supports customers’ drug products with advanced equipment, innovative technology, and a breadth of experienced team members.

RECENT ARTICLES

MichBio Hiring: Intern, Association Membership & Resource Analytics

April 15, 2025
MichBio seeks a highly motivated individual who can work creatively in a small team environment and assist in data mining, compilation, and research.

Bio Survey Underscores Impacts of Tariffs for Businesses

April 11, 2025
The Biotechnology Innovation Organization (BIO), of which MichBio is a state affiliate recently released the results of a survey of its members, noting that “U.S. Biotechs Sound the Alarm” on tariff impacts. The findings include: Tariffs on European Union and Canadian imports would increase manufacturing costs for 94% and 82% of biotech firms, respectively. 70% of companies anticipate higher manufacturing costs due to tariffs on China. Tariffs on the European Union would force 50% of biotech firms to identify new research and manufacturing partners. More than 50% of biotech firms predict “increased difficulty” in funding and conducting research if EU tariffs are enacted. 80% of biotech firms would need at least 12 months to find alternative suppliers; 44% would need over two years. The survey noted that sudden tariffs would fundamentally punish American companies, threaten vital research projects and imperil United States leadership in biomedical science. Read BIO’s press release , along with an one-pager summarizing the survey results. 

Amid Proposed Cuts, Commission Calls For $15B NIH Support

April 10, 2025
A federal commission, in a new report , is calling for $15 billion in new financing to reinforce the United States’ biotech leadership amid encroaching competition from China. This comes against a backdrop where the Trump Administration has proposed severe cuts to NIH operations and funding. The National Security Commission on Emerging Biotechnology was created by Congress in 2022 to explore how biotechnology advancements could shape the economy and national security. The body quickly focused on China, as that government has gone about gathering Americans’ genetic information and intellectual property in the biotech space and resourcing their cluster’s rapid growth. The report’s 49 recommendations, organized across six strategic pillars, offer a bold and actionable framework to protect U.S. biotech intellectual property and bolster drug development, agriculture, and biological weapons defense: Prioritize biotechnology at the national level Mobilize the private sector to get U.S. products to scale Maximize the benefits of biotechnology for defense Out-innovate our strategic competitors Build the biotechnology workforce of the future Mobilize the collective strengths of our allies and partners The report calls for $1 billion to create an investment fund, more than $6 billion for large-scale research challenges, and a build-up of biomanufacturing sites across the country. Also, it calls for new legislation barring companies that work with U.S. national security agencies or health agencies from using certain Chinese biotech suppliers. The commission doesn’t have the power to authorize any changes but can make recommendations and advise members of Congress. BIO issued a statement in support.